Optimizing vs. matching: response strategy in a probabilistic learning task is associated with negative symptoms of schizophrenia.
Previous research indicates that behavioral performance in simple probability learning tasks can be organized into response strategy classifications that are thought to predict important personal characteristics and individual differences. Typically, relatively small proportion of subjects can be identified as optimizers for effectively exploiting the environment and choosing the more rewarding stimulus nearly all of the time. In contrast, the vast majority of subjects behaves sub-optimally and adopts the matching or super-matching strategy, apportioning their responses in a way that matches or slightly exceeds the probabilities of reinforcement. In the present study, we administered a two-choice probability learning paradigm to 51 individuals with schizophrenia (SZ) and 29 healthy controls (NC) to examine whether there are differences in the proportion of subjects falling into these response strategy classifications, and to determine whether task performance is differentially associated with symptom severity and neuropsychological functioning. Although the sample of SZ patients did not differ from NC in overall rate of learning or end performance, significant clinical differences emerged when patients were divided into optimizing, super-matching and matching subgroups based upon task performance. Patients classified as optimizers, who adopted the most advantageous learning strategy, exhibited higher levels of positive and negative symptoms than their matching and super-matching counterparts. Importantly, when both positive and negative symptoms were considered together, only negative symptom severity was a significant predictor of whether a subject would behave optimally, with each one standard deviation increase in negative symptoms increasing the odds of a patient being an optimizer by as much as 80%. These data provide a rare example of a greater clinical impairment being associated with better behavioral performance.
Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA. zkasanova@mprc.umaryland.edu
Zuzana
Z
Kasanova
James A
JA
Waltz
Gregory P
GP
Strauss
Michael J
MJ
Frank
James M
JM
Gold
D000328:Adult; D001526:Behavioral Symptoms / Q000209:etiology*; D002755:Choice Behavior / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011337:Probability Learning; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000150:complications*; D012565:Schizophrenic Psychology
J Exp Anal Behav. 1970 Mar;13(2):243-66
16811440
Neuroreport. 2008 Jan 8;19(1):55-8
18281892
Prog Neurobiol. 2010 Nov;92(3):345-69
20558235
Am J Psychol. 1958 Dec;71(4):710-7
13627279
Schizophr Bull. 2008 Sep;34(5):848-55
18628272
Neuroimage. 2004 Feb;21(2):733-43
14980576
Biol Psychiatry. 2004 Sep 1;56(5):301-7
15336511
Biol Psychiatry. 2007 Oct 1;62(7):756-64
17300757
Philos Trans R Soc Lond B Biol Sci. 2007 May 29;362(1481):933-42
17395573
Brain. 2007 Sep;130(Pt 9):2387-400
17690132
Biol Psychiatry. 2001 Jan 1;49(1):71-7
11163782
J Exp Anal Behav. 1974 Jul;22(1):231-42
16811782
Biol Psychiatry. 2011 Mar 1;69(5):424-31
21168124
J Exp Psychol. 1954 Apr;47(4):225-34
13152299
PLoS One. 2008;3(11):e3795
19030101
Schizophr Res. 2008 Feb;99(1-3):200-7
17693060
Neuropsychologia. 2005;43(11):1598-608
16009242
Am J Psychiatry. 1996 May;153(5):714-7
8615422
Nature. 2006 Jun 15;441(7095):876-9
16778890
J Exp Anal Behav. 1983 Nov;40(3):321-31
16812350
J Exp Psychol. 1959 May;57(5):294-8
13654638
Am J Psychiatry. 2003 Jan;160(1):13-23
12505794
J Math Psychol. 1998 Jun;42(2/3):266-86
9710551
J Exp Psychol. 1951 Apr;41(4):291-7
14850645
Neuron. 2006 Jun 1;50(5):781-9
16731515
J Exp Psychol. 1956 Sep;52(3):177-88
13357700
Neuropsychopharmacology. 2008 Feb;33(3):473-9
17473838
J Exp Psychol. 1963 Nov;66:521-2
14082008
Schizophr Res. 1999 Jan 4;35(1):69-75
9988842
Philos Trans R Soc Lond B Biol Sci. 2007 Sep 29;362(1485):1531-43
17428782
Neuropsychopharmacology. 2010 Nov;35(12):2427-39
20720534
Brain Res. 2007 Jun 11;1153:111-21
17459346
Nature. 2006 May 11;441(7090):223-6
16633341
Psychol Rev. 2006 Apr;113(2):300-326
16637763
Schizophr Res. 1992 Mar;6(3):201-8
1571313
Science. 2004 Jun 18;304(5678):1782-7
15205529
Lancet. 2009 Aug 22;374(9690):635-45
19700006
Schizophr Res. 2007 Jul;93(1-3):296-303
17482797
Neuropsychopharmacology. 2009 May;34(6):1567-77
19052540